Preclinical investigations reveal the broad-spectrum neutralizing activity of peptide pep19-2.5 on bacterial pathogenicity factors

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 3, 2013, Pages 1480-1487

  Heinbockel, Lena ^a   Sánchez Gómez, Susana ^b   De Tejada, Guillermo Martinez ^b   Dömming, Sabine ^c   Brandenburg, Julius ^a   Kaconis, Yani ^a   Hornef, Mathias ^d   Dupont, Aline ^d   Marwitz, Sebastian ^a   Goldmann, Torsten ^a   Ernst, Martin ^a   Gutsmann, Thomas ^a   Schürholz, Tobias ^c   Brandenburg, Klaus ^a  

^a RESEARCH CENTER BORSTEL   (Germany)

^b UNIVERSITY OF NAVARRA   (Spain)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN; ANTIINFECTIVE AGENT; CEFTRIAXONE; CIPROFLOXACIN; ENDOTOXIN; ERYTHROMYCIN; IMIPENEM; PEP19 2.5 PROTEIN; POLYMYXIN B; TETRACYCLINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTEREMIA; BINDING AFFINITY; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BINDING; DRUG DESIGN; DRUG POTENTIATION; ENDOTOXEMIA; FEMALE; HUMAN; HUMAN TISSUE; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SALMONELLA ENTERICA; SINGLE DRUG DOSE; STAPHYLOCOCCUS AUREUS; SURVIVAL;

AMINO ACID SEQUENCE; ANIMALS; ANTI-BACTERIAL AGENTS; BACTEREMIA; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; ENDOTOXEMIA; FEMALE; HUMANS; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PEPTIDES; SEPSIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; SURVIVAL ANALYSIS; VIRULENCE FACTORS;

EID: 84874058565     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02066-12     Document Type: Article

References (44)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. 2001. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29:1303-1310.
2. Wang HE, Shapiro NI, Angus DC, Yealy DM. 2007. National estimates of severe sepsis in United States emergency departments. Crit. Care Med. 35:1928 -1936.
3. Singer P, Cohen JD. 2011. The Surviving Sepsis Campaign guidelines: should we follow? Isr. Med. Assoc. J. IMAJ. 13:692- 693.
4. Stone R. 1994. Search for sepsis drugs goes on despite past failures. Science 264:365-367.
5. Suffredini AF, Munford RS. 2011. Novel therapies for septic shock over the past 4 decades. JAMA 306:194 -199.
6. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL. 2008. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit. Care Med. 36: 296-327.
7. Cohen J. 2009. Non-antibiotic strategies for sepsis. Clin. Microbiol. Infect. 15:302-307.
8. Nahra R, Dellinger RP. 2008. Targeting the lipopolysaccharides: still a matter of debate? Curr. Opin. Anaesthesiol. 21:98 -104.
9. Kurokawa K, Ryu KH, Ichikawa R, Masuda A, Kim MS, Lee H, Chae JH, Shimizu T, Saitoh T, Kuwano K, Akira S, Dohmae N, Nakayama H, Lee BL. 2012. Novel bacterial lipoprotein structures conserved in low-GC content Gram-positive bacteria are recognized by Toll-like receptor 2. J. Biol. Chem. 287:13170 -13181.
10. Lopez-Bojorquez LN, Dehesa AZ, Reyes-Teran G. 2004. Molecular mechanisms involved in the pathogenesis of septic shock. Arch. Med. Res. 35:465- 479.
11. Aderem A, Ulevitch RJ. 2000. Toll-like receptors in the induction of the innate immune response. Nature 406:782-787.
12. Alexander C, Rietschel ET. 2001. Bacterial lipopolysaccharides and innate immunity. J. Endotoxin Res. 7:167-202.
13. Annane D, Bellissant E, Cavaillon JM. 2005. Septic shock. Lancet 365: 63-78.
14. Cohen J. 2002. The immunopathogenesis of sepsis. Nature 420:885- 891.
15. Opal SM. 2007. The host response to endotoxin, antilipopolysaccharide strategies, and the management of severe sepsis. Int. J. Med. Microbiol. 297:365-377.
16. Andrä J, Howe J, Garidel P, Rossle M, Richter W, Leiva-Leon J, Moriyon I, Bartels R, Gutsmann T, Brandenburg K. 2007. Mechanism of interaction of optimized Limulus-derived cyclic peptides with endotoxins: thermodynamic, biophysical and microbiological analysis. Biochem. J. 406:297-307.
17. Vallespi MG, Alvarez-Obregon JC, Rodriguez-Alonso I, Montero T, Garay H, Reyes O, Arana MJ. 2003. A Limulus anti-LPS factor-derived peptide modulates cytokine gene expression and promotes resolution of bacterial acute infection in mice. Int. Immunopharmacol. 3:247-256.
18. Ren JD, Gu JS, Gao HF, Xia PY, Xiao GX. 2008. A synthetic cyclic peptide derived from Limulus anti-lipopolysaccharide factor neutralizes endotoxin in vitro and in vivo. Int. Immunopharmacol. 8:775-781.
19. Zähringer U, Lindner B, Rietschel ET. 1994. Molecular structure of lipid A, the endotoxic center of bacterial lipopolysaccharides. Adv. Carbohydr. Chem. Biochem. 50:211-276.
20. Gutsmann T, Razquin-Olazaran I, Kowalski I, Kaconis Y, Howe J, Bartels R, Hornef M, Schürholz T, Rossle M, Sanchez-Gomez S, Moriyon I, Martinez de Tejada G, Brandenburg K. 2010. New antiseptic peptides to protect against endotoxin-mediated shock. Antimicrob. Agents Chemother. 54:3817-3824.
21. Kaconis Y, Kowalski I, Howe J, Brauser A, Richter W, Razquin- Olazaran I, Inigo-Pestana M, Garidel P, Rossle M, Martinez de Tejada G, Gutsmann T, Brandenburg K. 2011. Biophysical mechanisms of endotoxin neutralization by cationic amphiphilic peptides. Biophys. J. 100: 2652-2661.
22. Galanos C, Lüderitz O, Westphal O. 1969. A new method for the extraction of R lipopolysaccharides. Eur. J. Biochem. 9:245-249.
23. Howe J, Andrä J, Conde R, Iriarte M, Garidel P, Koch MH, Gutsmann T, Moriyon I, Brandenburg K. 2007. Thermodynamic analysis of the lipopolysaccharide-dependent resistance of gram-negative bacteria against polymyxin B. Biophys. J. 92:2796 -2805.
24. Droemann D, Rupp J, Goldmann T, Uhlig U, Branscheid D, Vollmer E, Kujath P, Zabel P, Dalhoff K. 2007. Disparate innate immune responses to persistent and acute Chlamydia pneumoniae infection in chronic obstructive pulmonary disease. Am. J. Resp. Crit. Care Med. 175:791-797.
25. Thornsberry C, McDougal LK. 1983. Successful use of broth microdilution in susceptibility tests for methicillin-resistant (heteroresistant) staphylococci. J. Clin. Microbiol. 18:1084 -1091.
26. Sanchez-Gomez S, Lamata M, Leiva J, Blondelle SE, Jerala R, Andrä J, Brandenburg K, Lohner K, Moriyon I, Martinez-de-Tejada G. 2008. Comparative analysis of selected methods for the assessment of antimicrobial and membrane-permeabilizing activity: a case study for lactoferricin derived peptides. BMC Microbiol. 8:196. doi:10.1186/1471-2180-8 -196.
27. Eliopoulos GM, Moellering RCJ. 1996. Antimicrobial combinations, p 330-393. In Lorian V (ed), Antibiotics in laboratory medicine, vol. 4. Williams & Wilkins, Baltimore, MD.
28. Galanos C, Freudenberg MA, Reutter W. 1979. Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc. Natl. Acad. Sci. U. S. A. 76:5939 -5943.
29. Bucklin SE, Morrison DC. 1995. Differences in therapeutic efficacy among cell wall-active antibiotics in a mouse model of gram-negative sepsis. J. Infect. Dis. 172:1519 -1527.
30. Evans ME, Pollack M. 1993. Effect of antibiotic class and concentration on the release of lipopolysaccharide from Escherichia coli. J. Infect. Dis. 167:1336 -1343.
31. Engel C, Brunkhorst FM, Bone HG, Brunkhorst R, Gerlach H, Grond S, Gruendling M, Huhle G, Jaschinski U, John S, Mayer K, Oppert M, Olthoff D, Quintel M, Ragaller M, Rossaint R, Stuber F, Weiler N, Welte T, Bogatsch H, Hartog C, Loeffler M, Reinhart K. 2007. Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med. 33:606-618.
32. U.S. Food and Drug Administration. 2011. FDA drug safety communication: voluntary market withdrawal of Xigris due to failure to show a survival benefit. U.S. Food and Drug Administration, Washington, DC.
33. Sweeney DA, Danner RL, Eichacker PQ, Natanson C. 2008. Once is not enough: clinical trials in sepsis. Intensive Care Med. 34:1955-1960.
34. Seam N, Suffredini AF. 2007. Mechanisms of sepsis and insights from clinical trials. Drug Discov. Today. Dis. Mech. 4:83-93.
35. Angus DC, Birmingham MC, Balk RA, Scannon PJ, Collins D, Kruse JA, Graham DR, Dedhia HV, Homann S, MacIntyre N. 2000. E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators. JAMA 283:1723-1730.
36. Schuerholz T, Brandenburg K, Marx G. 2012. Antimicrobial peptides and their potential application in inflammation and sepsis. Crit. Care 16:207.
37. Bowdish DM, Davidson DJ, Lau YE, Lee K, Scott MG, Hancock RE. 2005. Impact of LL-37 on anti-infective immunity. J. Leukoc. Biol. 77: 451-459.
38. Bowdish DM, Davidson DJ, Hancock RE. 2005. A re-evaluation of the role of host defence peptides in mammalian immunity. Curr. Protein Pept. Sci. 6:35-51.
39. Andrä J, Koch MH, Bartels R, Brandenburg K. 2004. Biophysical characterization of endotoxin inactivation by NK-2, an antimicrobial peptide derived from mammalian NK-lysin. Antimicrob. Agents Chemother. 48: 1593-1599.
40. Giuliani A, Pirri G, Rinaldi AC. 2010. Antimicrobial peptides, p 137-154. In Giuliani A, Rinaldi AC (ed), Methods in molecular biology. Springer Science-Business Media, New York, NY.
41. Fjell CD, Hiss JA, Hancock RE, Schneider G. 2012. Designing antimicrobial peptides: form follows function. Nat. Rev. Drug Discov. 11:37-51.
42. Hancock RE, Sahl HG. 2006. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 24:1551- 1557.
43. Periti P, Mazzei T. 1998. Antibiotic-induced release of bacterial cell wall components in the pathogenesis of sepsis and septic shock: a review. J. Chemother. 10:427- 448.
44. Brandenburg K. April 2009. Novel antimicrobial peptides. Patent no. PCT/EP2009/002565.